Patient-Focused Treatment Decisions in the Management of Non-Small Cell Lung Cancer (NSCLC)

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
AstraZeneca, Bayer Healthcare, Merck Sharp & Dohme Corp.,
and Novartis Pharmaceuticals Corporation

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 228,820 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 135,720 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. As more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Healthcare professionals (HCPs) need to be aware of information regarding tumor-specific diagnosis, expanding treatment options, and supporting data to maximize the care of their patients. With so many effective treatment options becoming available, it is critical to inform medical directors, oncologists and nurses about these agents, and strategies to effectively manage NSCLC patients.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of advanced non-small cell lung cancer (NSCLC), including factors that contribute to poor prognosis and increased costs

  • Assess the most recent testing guidelines for NSCLC, including clinically relevant biomarkers, recommended testing modalities, and implications for currently available and evolving treatments

  • Compare and contrast efficacy and safety profiles and recent clinical data of current and emerging therapies for the treatment of metastatic NSCLC

  • Explore the evolving role of TRK, MET, and KRAS inhibitors for patients with advanced NSCLC

  • Evaluate the emerging role of EGFR TKIs as adjuvant therapy for patients with EGFR-mutant NSCLC

  • Discuss methods to enable optimal cost management of novel therapies, including targeted therapies and immunotherapies, to be realized by multiple NSCLC stakeholders including managed care organizations

     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

Gary Owens, MD has no financial relationships with ineligible companies to disclose.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
AstraZeneca, Bayer Healthcare, Merck Sharp & Dohme Corp.,
and Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue